Eledon Pharmaceuticals, Inc. (ELDN)

Eledon Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	14.64	-36.18	-116.54	-87.97	-34.51	-22.81
Depreciation & Amortization	-	-	-	-	-	0.01
Stock-Based Compensation	13.92	13.12	6.55	8.15	7.9	3.17
Other Adjustments	-100.52	-32.92	75.38	49.02	-2.16	4.6
Changes in Accounts Payable	7.63	7.75	-2.6	2.08	2.14	-0.04
Changes in Other Operating Activities	-0.64	0.96	-2.32	0.29	-2.3	-0.14
Operating Cash Flow	-64.53	-47.27	-39.53	-28.42	-28.91	-15.21
Purchases of Investments	-166.16	-156.13	-78.29	-	-	-
Proceeds from Sale of Investments	124.82	85.82	33	-	-	-
Other Investing Activities	-	-	-	-	-	11.04
Investing Cash Flow	-41.33	-70.31	-45.29	-	-	11.04
Issuance of Common Stock	-	133.52	33.02	-	0	14.38
Repurchase of Common Stock	-	-	-	-	-	-0.03
Net Common Stock Issued (Repurchased)	-	133.52	33.02	-	0	14.36
Issuance of Preferred Stock	-	-	-	-	-	95.23
Net Preferred Stock Issued (Repurchased)	-	-	-	-	-	95.23
Other Financing Activities	-	-	-	-	-0.45	-
Financing Cash Flow	-	133.52	33.02	-	-0.45	109.58
Net Cash Flow	-20.3	15.94	-51.8	-28.42	-29.36	105.4
Ending Cash & Cash Equivalents	-20.3	15.94	-51.8	-28.42	-29.36	105.4
Free Cash Flow	-64.53	-47.27	-39.53	-28.42	-28.91	-15.21
Free Cash Flow Per Share	-0.93	-0.97	-1.61	-1.99	-1.95	-10.48
Levered Free Cash Flow	22.06	-26.61	-121.45	-85.6	-39.37	-23.79
Unlevered Free Cash Flow	-80.91	-61.02	-47.92	-86.06	-39.37	-18.96

Updated Aug 14, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q